March 10, 2023
John Shakow discusses the administrative dispute resolution rule for the 340B drug discount program and its impact on manufacturers
February 27, 2023
Eva Temkin discusses how organizations, states and courts are impacting the FDA’s ability to approve and regulate drugs
February 14, 2023
Beverly Lorell comments on issues of data integrity and why it represents high stakes for both sponsors and clinical investigators
February 10, 2023
K&S to lobby on behalf of Taurx Pharmaceuticals
February 7, 2023
King & Spalding Lawyers Named to Leadership Council on Legal Diversity Fellowship, Pathfinder Programs